Last update 11 Jul 2024

Canakinumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-IL-1 beta monoclonal antibody, Antibody A, Canakinumab (Genetical Recombination)
+ [8]
Target
Mechanism
IL-1β inhibitors(Interleukin-1 beta inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOverseas New Drugs Urgently Needed in Clinical Settings (CN), Orphan Drug (JP), Fast Track (US), Breakthrough Therapy (US)
Login to view First Approval Timeline

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Arthritis, Gouty
IS
23 Oct 2009
Arthritis, Gouty
EU
23 Oct 2009
Arthritis, Gouty
NO
23 Oct 2009
Arthritis, Gouty
LI
23 Oct 2009
Juvenile Arthritis
EU
23 Oct 2009
Periodic Fever Syndrome
LI
23 Oct 2009
Periodic Fever Syndrome
NO
23 Oct 2009
Periodic Fever Syndrome
EU
23 Oct 2009
Periodic Fever Syndrome
IS
23 Oct 2009
Periodic Fever, Familial, Autosomal Dominant
IS
23 Oct 2009
Periodic Fever, Familial, Autosomal Dominant
EU
23 Oct 2009
Periodic Fever, Familial, Autosomal Dominant
LI
23 Oct 2009
Periodic Fever, Familial, Autosomal Dominant
NO
23 Oct 2009
Still's Disease, Adult-Onset
NO
23 Oct 2009
Still's Disease, Adult-Onset
EU
23 Oct 2009
Still's Disease, Adult-Onset
IS
23 Oct 2009
Still's Disease, Adult-Onset
LI
23 Oct 2009
Cryopyrin-Associated Periodic Syndromes
CH
27 Sep 2009
Familial cold urticaria
US
17 Jun 2009
Muckle-Wells Syndrome
US
17 Jun 2009
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Schnitzler SyndromePhase 2
EU
-
Muckle-Wells SyndromePhase 1
IN
01 Apr 2007
Muckle-Wells SyndromePhase 1
FR
01 Apr 2007
Muckle-Wells SyndromePhase 1
GB
01 Apr 2007
Schnitzler SyndromePhase 1
EU
-
Familial cold urticariaDiscovery
ES
01 May 2008
Familial cold urticariaDiscovery
TR
01 May 2008
Familial cold urticariaDiscovery
IN
01 May 2008
Muckle-Wells SyndromeDiscovery
DE
01 Apr 2007
Muckle-Wells SyndromeDiscovery
ES
01 Apr 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
Advanced Lung Non-Small Cell Carcinoma
First line
C-reactive protein | IL-6
643
(pycogmdcec) = yzehdwbsae nazslnsibr (rsfiudxooo )
Negative
10 Jan 2024
Placebo
(pycogmdcec) = xyiouflaqk nazslnsibr (rsfiudxooo )
Phase 2
27
(nbzcsnlyzq) = nmuzhtvmtk rroqlzsxho (jmfhedrmyn )
-
09 Dec 2023
Not Applicable
-
-
mkglzrfruf(znfjsjjgfx) = developed in 7 NOMID patients (20 % of screened patients) on high-dose long-term, anakinra treatment; one patient developed systemic AIL1RAP amyloidosis anebxldpjb (ypvdgrwenp )
-
14 Nov 2023
Not Applicable
101
fayjntlhwt(nkolijwhag) = dpwyxstbfx rtyilojfjn (taffqhcpqf )
Positive
14 Nov 2023
Phase 2
Lung Cancer
Canakinumab
15
(ajeejxnvip) = grade 2 neutropenia (n= 4) leading to treatment disruption or discontinuation (no active infection) kkczpscdmr (npusenocut )
Positive
10 Sep 2023
control group
Phase 3
-
(Part I)
(waynpvufux) = doqfzqcumk pkjykpssza (ykjefdgtaw )
Positive
25 Aug 2023
ILARIS + Part II
(amwrwazkpr) = mspkzqtajf argtpoqlli (boerijyuld )
Phase 3
181
(urnjrmsujx) = tgeajtinuj uilsxgxccx (fraseyswaa )
Positive
25 Aug 2023
Placebo
(TRAPS)
(urnjrmsujx) = mfiacujyvk uilsxgxccx (fraseyswaa )
Phase 3
84
(wxohcydesm) = tgzkbpltxi xvdlpmfwqz (vbpmosyumb )
Positive
25 Aug 2023
Placebo
(wxohcydesm) = fgtcrchmvz xvdlpmfwqz (vbpmosyumb )
Phase 3
851
(Study 1)
(ptyvsyelxj) = fuftnsgvea pbvwqjwpgr (oolahosiaz, 2.42)
Positive
25 Aug 2023
(ptyvsyelxj) = eurlmsjxby pbvwqjwpgr (oolahosiaz, 2.40)
Phase 3
-
rjfafsmxkv(uatdrpnnal) = sbawgmwnzp knghmshqui (xzlvuepkxf )
Positive
25 Aug 2023
Placebo
rjfafsmxkv(uatdrpnnal) = wiitklqjob knghmshqui (xzlvuepkxf )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free